Centre for Oncology and Immunology Limited Hong Kong SAROn-site Full Time 6 - 10 Year Mid-Senior level Job Responsibilities: Applications are invited for appointment as Assistant Technical Manager (Ref.: H03/2023/04), to commence as soon as possible, on a fixed-term basis, with the possibility of renewal subject to satisfactory performance and mutual agreement. The appointee will assist the Laboratory Manager and research team in: Operating and maintaining shared equipment in Imaging, Flow Cytometry and Drug Screening system; Training users and organizing workshops; Developing and implementing standard operation protocols for users; Performing administrative duties as assigned; Assisting collaborative research projects in discovery of cancer biomarkers using large scale multi-omics approach, organoid technology and novel animal models, as well as anti-cancer or immuno-oncology drug development. Qualifications and Skills: Bachelor degree or above in Biomedical Sciences or related discipline; Minimum 6 years of instrument operation experience in biomedical research laboratory, preferably in Flow Cytometry, Imaging, NGS, CRISPR, Drug Screening, and Single Cell technology; Proactive, dynamic, mature with superior interpersonal skills with all levels of staff and external stakeholders and collaborators; Strong teamwork attitude and ability to manage up, down; A good command of written and spoken English, with excellent presentation skills. The appointee shall work in Hong Kong Science and Technology Park. Overseas graduates are welcome to apply, the qualification awarding institution should be the top 100 institutions for STEM-related subjects in QS/Shanghai Jiao Tong Uni/Times Higher Education/U. S. News world university rankings. A highly competitive salary commensurate with qualifications and experience will be offered, in addition to annual leave and medical benefits. How to apply: Applicants should submit their up-to-date C. V. and research publication list (where applicable), quoting the job reference number, with information of current/expected remuneration and availability, to career@coinno.hk. Review of applications will commence as soon as possible and continue until the posts are filled. The personal data provided in your application process will be used for recruitment and other employment-related purposes. The personal data may be transferred and disclosed to, and used by HKU Innovation Holdings Limited and The University of Hong Kong for the above purposes. We are an equal opportunities employer and welcome applications from all qualified candidates. Additional Information Job Level Mid-Senior level Publish Date10/01/2025 Job Ref. No. H03/2023/04 Job Function Laboratory Life Science Research & Development (R&D)Company Overview Digestive malignancies, including gastric, colorectal, liver and esophageal cancers as well as leukemias and lymphomas, are major health burdens in Asian countries. Today, gastrointestinal and liver cancers are becoming more common across Asia due to population aging, growth, and a rise in risk factors ranging from oncogenic pathogen infections to increased smoking and obesity. Under the auspices of the Inno HK initiative, the Centre for Oncology and Immunology aims to harness the power of biotechnology to develop innovative therapies to combat these hard-to-treat malignancies and bring hope to millions of cancer patients around the world. The Centre for Oncology and Immunology is co-led by Professor Tak MAK and Professor Suet-yi LEUNG of the Department of Pathology at HKUMed in discovering novel therapies in cancer treatment. The Centre’s research team comprises globally renowned researchers who bring with them a wealth of complementary expertise and experience in oncology research, technology adoption, and commercialization. Individually, their research programs have led to major breakthroughs, including the devising of immunotherapy and checkpoint inhibition strategies that have been adopted as anti-cancer treatments, the establishment of next-generation organoid-based cell models for precision oncology, and the development of a diagnostic test for Lynch Syndrome (hereditary colon cancer). The Centre will employ novel functional screens as well as genomic and proteomic techniques to identify novel “druggable” cancer targets. Leveraging the translational and clinical trial expertise of its lead scientists, the Centre will establish a number of advanced technical platforms to facilitate its overall goal of bringing candidate drugs and novel immunotherapy approaches into clinics. Success in this venture will address pressing unmet medical needs and establish Hong Kong as a leading hub of innovative anti-cancer and immuno-oncology drug development.
#J-18808-Ljbffr